Clinical Trials Logo

Renal Cell Carcinoma clinical trials

View clinical trials related to Renal Cell Carcinoma.

Filter by:

NCT ID: NCT05949424 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

OPTI-DOSE
Start date: May 2024
Phase: Phase 4
Study type: Interventional

The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same. The trial population consists of 30 patients aged 65 years or older, who are starting treatment with one of these anti cancer tablet treatments: pazopanib, olaparib, lenvatinib, sunitinib or palbociclib. The control group (half of the participants) will be treated with the standard-of-care, the interventional group will start with the lowest dose of the anti cancer tablets as described in the drug label. The dose will be increased every two weeks in case of good tolerability. Results of this pilot study will be used to inform the design of the larger randomised phase 2 trial.

NCT ID: NCT05941169 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy

PrimerX
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The benefit of deferred Cytoreductive Nephrectomy (CN) has to be re-assessed in the context of IO +IO and IO + TKI systemic treatment. Given the benefit of CN in the setting of first generation immunotherapy, it is conceivable that both trials underestimated the benefit of CN, in absence of immunotherapy.

NCT ID: NCT05931393 Recruiting - Clinical trials for Renal Cell Carcinoma

Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)

Start date: December 20, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the effects of a higher dose of cabozantinib or the effects of cabozantinib-nivolumab combination in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment. The study will have two parts or "cohorts". - Cohort 1: cabozantinib 80mg daily - Cohort 2: cabozantinib 40mg daily with nivolumab The cohort assignment will be determined by investigator, based on how much cabozantinib the participant is able to safely receive.

NCT ID: NCT05917106 Recruiting - Clinical trials for Renal Cell Carcinoma

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

Start date: December 26, 2022
Phase:
Study type: Observational [Patient Registry]

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

NCT ID: NCT05902377 Recruiting - Clinical trials for Renal Cell Carcinoma

68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center study in patients with renal cell carcinoma. The goal is to determine the sensitivity and specificity of 68Ga-NY104 PET/CT in the detection of clear cell renal cell carcinoma.

NCT ID: NCT05887245 Recruiting - Clinical trials for Renal Cell Carcinoma

Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy

Start date: April 17, 2023
Phase:
Study type: Observational

The aim of this study is to gain a better understanding of the phenomenon of adherent perinephric fat (APF), which occurs in some patients undergoing partial nephrectomy (PN). This phenomenon, so-called "toxic fat", is a commonly recognized problem among urologists, but its significance has not yet been fully understood. The study aims to identify new clinical risk factors for APF occurrence and evaluate its impact on functional, perioperative, and oncological treatment outcomes. The study will be conducted on patients who are qualified for PN surgery. Prior to the surgical procedure, venous blood will be collected, which will be used for various measurements, such as blood morphology, kidney parameters, inflammation markers, liver function tests, glucose, and lipid profile. In addition, medical data will be collected concerning the patient's overall health, observed changes in the kidney, perioperative course, hospitalization, and histopathological characteristics of the tumor. After treatment, patients will be followed up for up to 60 months. The knowledge gained from this study can significantly assist in making decisions about surgical treatment and thus contribute to improving the treatment outcomes of patients with kidney tumors.

NCT ID: NCT05867303 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Start date: June 5, 2023
Phase: Phase 1
Study type: Interventional

Safety study of RC198 in Subjects with Solid Tumors.

NCT ID: NCT05863052 Active, not recruiting - Melanoma Clinical Trials

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Start date: January 31, 2022
Phase:
Study type: Observational

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

NCT ID: NCT05858736 Recruiting - Colorectal Cancer Clinical Trials

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

PRESERVE-009
Start date: July 11, 2023
Phase: Phase 1
Study type: Interventional

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

NCT ID: NCT05843305 Not yet recruiting - Solid Tumor Clinical Trials

A Study of BPI-452080 in Subjects With Solid Tumors

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors